Literature DB >> 20068082

New insights into checkpoint kinase 1 in the DNA damage response signaling network.

Yun Dai1, Steven Grant.   

Abstract

The DNA damage response (DDR) represents a complex network of multiple signaling pathways involving cell cycle checkpoints, DNA repair, transcriptional programs, and apoptosis, through which cells maintain genomic integrity following various endogenous (metabolic) or environmental stresses. In cancer treatment, the DDR occurs in response to various genotoxic insults by diverse cytotoxic agents and radiation, representing an important mechanism limiting chemotherapeutic and radiotherapeutic efficacy. This has prompted the development of agents targeting DDR signaling pathways, particularly checkpoint kinase 1 (Chk1), which contributes to all currently defined cell cycle checkpoints, including G1/S, intra-S-phase, G2/M, and the mitotic spindle checkpoint. Although numerous agents have been developed with the primary goal of enhancing the activity of DNA-damaging agents or radiation, the therapeutic outcome of this strategy remains to be determined. Recently, new insights into DDR signaling pathways support the notion that Chk1 represents a core component central to the entire DDR, including direct involvement in DNA repair and apoptotic events in addition to checkpoint regulation. Together, these new insights into the role of Chk1 in the DDR machinery could provide an opportunity for novel approaches to the development of Chk1 inhibitor strategies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20068082      PMCID: PMC2939735          DOI: 10.1158/1078-0432.CCR-09-1029

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  59 in total

Review 1.  Cell-cycle checkpoints and cancer.

Authors:  Michael B Kastan; Jiri Bartek
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

Review 2.  Regulation of DNA repair throughout the cell cycle.

Authors:  Dana Branzei; Marco Foiani
Journal:  Nat Rev Mol Cell Biol       Date:  2008-02-20       Impact factor: 94.444

3.  A role for Chk1 in blocking transcriptional elongation of p21 RNA during the S-phase checkpoint.

Authors:  Rachel Beckerman; Aaron J Donner; Melissa Mattia; Melissa J Peart; James L Manley; Joaquin M Espinosa; Carol Prives
Journal:  Genes Dev       Date:  2009-06-01       Impact factor: 11.361

4.  AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.

Authors:  Sonya D Zabludoff; Chun Deng; Michael R Grondine; Adam M Sheehy; Susan Ashwell; Benjamin L Caleb; Stephen Green; Heather R Haye; Candice L Horn; James W Janetka; Dongfang Liu; Elizabeth Mouchet; Shannon Ready; Judith L Rosenthal; Christophe Queva; Gary K Schwartz; Karen J Taylor; Archie N Tse; Graeme E Walker; Anne M White
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

5.  The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair.

Authors:  Claus Storgaard Sørensen; Lasse Tengbjerg Hansen; Jaroslaw Dziegielewski; Randi G Syljuåsen; Cecilia Lundin; Jiri Bartek; Thomas Helleday
Journal:  Nat Cell Biol       Date:  2005-01-23       Impact factor: 28.824

6.  Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control.

Authors:  Deborah Wilsker; Eva Petermann; Thomas Helleday; Fred Bunz
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-17       Impact factor: 11.205

7.  Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells.

Authors:  Yun Dai; Shuang Chen; Xin-Yan Pei; Jorge A Almenara; Lora B Kramer; Charis A Venditti; Paul Dent; Steven Grant
Journal:  Blood       Date:  2008-07-09       Impact factor: 22.113

8.  Regulation of chk1.

Authors:  Claudia Tapia-Alveal; Teresa M Calonge; Matthew J O'Connell
Journal:  Cell Div       Date:  2009-04-29       Impact factor: 5.130

9.  Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor.

Authors:  Shinji Mizuarai; Kazunori Yamanaka; Hiraku Itadani; Tsuyoshi Arai; Toshihide Nishibata; Hiroshi Hirai; Hidehito Kotani
Journal:  Mol Cancer       Date:  2009-06-08       Impact factor: 27.401

Review 10.  G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer.

Authors:  N Bucher; C D Britten
Journal:  Br J Cancer       Date:  2008-01-29       Impact factor: 7.640

View more
  186 in total

Review 1.  Recent progress in histochemistry and cell biology.

Authors:  Stefan Hübner; Athina Efthymiadis
Journal:  Histochem Cell Biol       Date:  2012-02-25       Impact factor: 4.304

2.  Modification of the DNA damage response by therapeutic CDK4/6 inhibition.

Authors:  Jeffry L Dean; A Kathleen McClendon; Erik S Knudsen
Journal:  J Biol Chem       Date:  2012-06-25       Impact factor: 5.157

Review 3.  Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?

Authors:  Tetyana V Bagnyukova; Ilya G Serebriiskii; Yan Zhou; Elizabeth A Hopper-Borge; Erica A Golemis; Igor Astsaturov
Journal:  Cancer Biol Ther       Date:  2010-11-01       Impact factor: 4.742

4.  Enhancement of arabinocytosine (AraC) toxicity to AML cells by a differentiation agent combination.

Authors:  Xuening Wang; Jonathan S Harrison; George P Studzinski
Journal:  J Steroid Biochem Mol Biol       Date:  2015-08-28       Impact factor: 4.292

5.  Finite Element Analysis of the Mouse Distal Femur with Tumor Burden in Response to Knee Loading.

Authors:  Feifei Jiang; Shengzhi Liu; Andy Chen; Bai-Yan Li; Alexander G Robling; Jie Chen; Hiroki Yokota
Journal:  Int J Orthop (Hong Kong)       Date:  2018-02-28

6.  Hypergrowth mTORC1 signals translationally activate the ARF tumor suppressor checkpoint.

Authors:  Alexander P Miceli; Anthony J Saporita; Jason D Weber
Journal:  Mol Cell Biol       Date:  2011-11-07       Impact factor: 4.272

7.  RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma.

Authors:  Kristina A Cole; Jonathan Huggins; Michael Laquaglia; Chase E Hulderman; Mike R Russell; Kristopher Bosse; Sharon J Diskin; Edward F Attiyeh; Rachel Sennett; Geoffrey Norris; Marci Laudenslager; Andrew C Wood; Patrick A Mayes; Jayanti Jagannathan; Cynthia Winter; Yael P Mosse; John M Maris
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-02       Impact factor: 11.205

8.  Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.

Authors:  Judith E Karp; Brian M Thomas; Jacqueline M Greer; Christopher Sorge; Steven D Gore; Keith W Pratz; B Douglas Smith; Karen S Flatten; Kevin Peterson; Paula Schneider; Karen Mackey; Tomoko Freshwater; Mark J Levis; Michael A McDevitt; Hetty E Carraway; Douglas E Gladstone; Margaret M Showel; Sabine Loechner; David A Parry; Jo Ann Horowitz; Randi Isaacs; Scott H Kaufmann
Journal:  Clin Cancer Res       Date:  2012-10-23       Impact factor: 12.531

9.  Checkpoint kinase 2 is required for efficient immunoglobulin diversification.

Authors:  Kathrin Davari; Samantha Frankenberger; Angelika Schmidt; Nils-Sebastian Tomi; Berit Jungnickel
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 10.  Improving the efficacy of chemoradiation with targeted agents.

Authors:  Meredith A Morgan; Leslie A Parsels; Jonathan Maybaum; Theodore S Lawrence
Journal:  Cancer Discov       Date:  2014-02-18       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.